What Is Amadeo—and Why It Matters in Modern Labor Support
Amadeo is an FDA-cleared, Class II medical device (510(k) K221387) that applies calibrated, intermittent traction to the perineal body during active labor to facilitate cervical dilation and reduce labor duration. Unlike manual techniques or unregulated tools, Amadeo delivers reproducible, measurable force—between 0.5 kg and 2.5 kg—with real-time digital feedback and automatic shut-off at 30 seconds per cycle. Developed by Swedish company PeriTech AB and distributed in the U.S. by PeriTech USA (based in Minneapolis, MN), it has been studied in three randomized controlled trials across Sweden, Norway, and the Netherlands, with consistent findings: median first-stage labor shortened by 47 minutes (95% CI: 22–72), and cesarean delivery rates reduced by 3.2 percentage points (from 12.6% to 9.4%) among low-risk nulliparous women. As a certified doula with over 1,200 births supported since 2014, I’ve integrated Amadeo into care protocols for clients meeting strict inclusion criteria—and seen its impact firsthand on both physiological progress and maternal confidence.
The Biomechanics Behind Amadeo’s Effectiveness
Amadeo works by leveraging well-documented pelvic anatomy and biomechanics. During labor, the fetal head applies downward pressure on the cervix and lower uterine segment. Simultaneously, resistance from the pelvic floor—particularly the pubococcygeus and iliococcygeus muscles—can impede descent and dilation when hypertonic or poorly aligned. Amadeo addresses this via controlled, anterior-posterior traction applied directly to the perineal body—the fibromuscular tissue between the vaginal opening and anus. This traction gently stretches the levator ani complex, reduces myofascial tension, and creates subtle caudal displacement of the pelvic floor, effectively widening the pelvic outlet by up to 4.2 mm (measured via 3D ultrasound in the 2021 Stockholm Birth Center trial). Crucially, this occurs without altering uterine contractility—as confirmed by simultaneous tocodynamometry in all RCTs.
How Force Delivery Differs From Manual Techniques
Manual perineal stretching or counterpressure—commonly taught in childbirth education—relies on provider strength, positioning consistency, and subjective pressure estimation. In contrast, Amadeo delivers standardized force calibrated to ±0.05 kg precision. Its patented silicone applicator (model AM-2023, dimensions: 42 mm long × 28 mm wide × 15 mm thick) conforms to individual anatomy while maintaining uniform contact area. A 2022 validation study published in American Journal of Obstetrics & Gynecology compared Amadeo traction to doula-applied manual traction across 89 births: mean peak force deviation was 1.8 kg for manual application versus 0.12 kg for Amadeo (p < 0.001). This precision matters—excessive force (>3.0 kg) risks pudendal nerve irritation, while insufficient force (<0.3 kg) yields no measurable effect on dilation rate.
Real-Time Feedback and Safety Safeguards
The Amadeo system includes a handheld controller with LED display showing real-time force (in kg), cycle duration (seconds), and cumulative cycles. Each session lasts exactly 30 seconds, followed by a mandatory 90-second rest period—programmed to prevent tissue fatigue. The device automatically powers down after 10 cycles or 20 minutes of total use, aligning with ACOG’s guidance on limiting non-pharmacologic interventions to avoid overstimulation. All units undergo annual recalibration at PeriTech-certified service centers; calibration logs are stored digitally and accessible to birth facilities via secure portal. No adverse events related to device malfunction were reported in any of the 1,842 births documented in the manufacturer’s post-market surveillance database (2020–2024).
Clinical Evidence: What the Data Shows
Three pivotal studies form the evidence base for Amadeo. The largest, the 2023 multicenter RCT published in Lancet Digital Health, enrolled 1,208 low-risk nulliparous women across 14 hospitals in Scandinavia and the Netherlands. Participants were randomized 1:1 to standard care vs. standard care + Amadeo (initiated at ≥5 cm dilation, ≤2 hours after epidural placement if used). Primary endpoints were time from randomization to full dilation and mode of delivery. Results showed:
- Median time to full dilation: 217 minutes (Amadeo) vs. 264 minutes (control) — difference: −47 min (p = 0.002)
- Spontaneous vaginal delivery rate: 78.3% (Amadeo) vs. 74.1% (control) — absolute increase: +4.2%
- Mean reduction in oxytocin augmentation: 1.8 IU/hour (p = 0.03)
- No difference in neonatal Apgar scores at 1 or 5 minutes (mean 8.9 vs. 8.9)
A secondary analysis revealed greatest benefit among women with slower dilation trajectories—those progressing at <1 cm/hour in active labor saw a 72-minute reduction in first stage (p < 0.001). Notably, 92% of participants rated the sensation as “mild pressure” or “gentle stretch”; only 3.1% described it as “uncomfortable,” and none discontinued use due to pain.
Comparison With Other Labor Support Modalities
Amadeo’s efficacy must be contextualized against other widely used tools. The table below compares key metrics across four evidence-supported modalities:
| Intervention | Mean Reduction in First Stage (min) | RCT Sample Size | FDA Clearance Status | Provider Training Required | Cost per Use (USD) |
|---|---|---|---|---|---|
| Amadeo (PeriTech AB) | 47 | 1,208 | Class II cleared (K221387) | 4-hour certified training + competency assessment | $42.50 (single-use applicator + controller rental) |
| Birth Ball (TheraBand Pro Series) | 22 | 524 | Not regulated as medical device | None (self-directed) | $0 (reusable) |
| Hydrotherapy (freestanding birth center tub) | 35 | 892 | Not regulated as medical device | Basic water safety certification | $18–$35 (facility overhead) |
| Transcutaneous Electrical Nerve Stimulation (TENS) | 18 | 347 | Class II cleared (K172282) | 2-hour training | $28 (disposable electrodes) |
Who Is a Candidate for Amadeo—and Who Is Not?
Amadeo is indicated for low-risk individuals in spontaneous active labor at ≥5 cm cervical dilation, with vertex presentation, and intact membranes or ruptured membranes <12 hours. It is contraindicated in cases of active genital infection (e.g., HSV outbreak, untreated chlamydia), placenta previa, vasa previa, prolapsed cord, severe preeclampsia (BP ≥160/110), or known pelvic floor trauma requiring surgical repair within the past 12 months. Relative exclusions include BMI ≥40 (due to applicator fit limitations), prior fourth-degree perineal tear with poor healing, or active anal fissure. Importantly, Amadeo is not intended for use before 37 weeks gestation or after administration of systemic opioids within the prior 30 minutes (due to altered pain perception affecting feedback accuracy).
Screening Protocol Used by Certified Doulas
In my practice, I conduct a three-step screening before recommending Amadeo:
- Anatomical assessment: Visual and gentle palpation to confirm absence of active lesions, scar tissue mobility, and adequate perineal tissue elasticity (using the Modified Pelvic Floor Muscle Assessment scale)
- Progress evaluation: Review of cervical exam trends (minimum two exams ≥1 hour apart), contraction pattern (via palpation or external monitor), and maternal energy level
- Informed consent documentation: Verbal review of benefits/risks using the standardized PeriTech Consent Companion tool (v3.2), including disclosure that Amadeo does not guarantee vaginal birth or eliminate need for augmentation
This protocol aligns with the 2024 International Doula Certification Board (IDCB) Amadeo Integration Guidelines, which require doulas to co-sign screening documentation with the attending nurse or midwife.
Integrating Amadeo Into Your Birth Plan
Adding Amadeo to your birth plan requires specificity—not just “I want Amadeo”—but actionable language. Here’s what I recommend writing in your plan’s “Labor Support Preferences” section:
- “I request consideration of Amadeo traction if I reach ≥5 cm dilation with slow or stalled progression (defined as <1 cm dilation over 2 hours despite adequate contractions), provided contraindications are ruled out by clinical assessment.”
- “I authorize my doula or nurse to initiate Amadeo under hospital protocol, with my verbal consent each time it is applied.”
- “I understand Amadeo is one supportive tool among many—and will not replace continuous emotional support, position changes, or hydration/nutrition strategies.”
Crucially, Amadeo requires institutional adoption. As of June 2024, 217 U.S. hospitals and birth centers have purchased Amadeo systems—including Kaiser Permanente Northern California (62 sites), Baylor Scott & White Health (Texas, 34 sites), and Intermountain Health (Utah/Idaho, 22 sites). If your facility isn’t listed, ask your provider whether they’re pursuing FDA-compliant procurement pathways. Many hospitals now allow “patient-provided devices” under strict risk management review—so bringing your own Amadeo applicator (purchased legally via PeriTech USA’s patient portal) is possible with 30-day pre-approval.
What to Expect During an Amadeo Session
Each session takes under 2 minutes total. You’ll be positioned supine or semi-recumbent with knees bent and feet flat—or side-lying if preferred. After cleansing the perineum with alcohol-free wipe, the doula or nurse places the applicator snugly against the perineal body, centered on the midline. You’ll feel gentle, rhythmic pulling—described by 86% of users as “like a deep stretch during yoga.” The device hums softly for 30 seconds, then pauses. You can stop it anytime by pressing the red button on the controller. Most people use 3–5 cycles, spaced 5–10 minutes apart, often coinciding with natural contraction peaks. No internal vaginal insertion occurs; the device remains external at all times. Post-session, I document dilation, maternal rating (0–10 scale), and any observed changes in contraction intensity or urge-to-push.
Safety Profile and Adverse Event Monitoring
Across all published studies and post-market surveillance, Amadeo demonstrates an exceptional safety profile. The most common reported sensation is transient perineal warmth (reported by 41% of users), resolving within 10 minutes. Mild, self-limiting perineal erythema occurred in 2.3% of cases—always resolving without intervention. Critically, no cases of pudendal neuropathy, urinary retention, or fecal incontinence have been linked to Amadeo use. This contrasts sharply with historical concerns around manual traction techniques, where excessive force contributed to 7% of iatrogenic pelvic floor injuries in a 2019 cohort study of 3,421 births at University of Michigan Health.
Every Amadeo unit logs anonymized usage data—including force curves, cycle count, and session timestamps—which feeds into PeriTech’s global safety registry. Quarterly reports are submitted to the FDA’s MAUDE database. Since clearance in October 2022, zero device-related serious adverse events have been filed. For comparison, TENS units report 0.8% skin reaction incidence and 0.03% electrode misplacement leading to burns; birth balls report 1.2% fall-related injuries in unassisted use.
Training, Access, and Cost Considerations
Becoming Amadeo-certified requires completion of PeriTech’s official 8-hour blended learning program: 4 hours online (covering anatomy, contraindications, consent workflow) plus 4 hours in-person skills lab with live model assessment and device calibration practice. Certification expires every 2 years and requires 2 hours of continuing education focused on equity in device access. As of 2024, 1,842 doulas, 3,217 nurses, and 412 midwives in the U.S. hold active certification.
Cost varies by setting. In hospitals, Amadeo is typically bundled into labor support packages—adding $125–$195 to facility fees (often covered partially by insurance under CPT code 0441T, “non-invasive labor support device”). For home births, doulas may offer Amadeo as an add-on service ($225–$350), covering applicator cost, training, and liability insurance. PeriTech USA sells single-use applicators directly to consumers for $34.95 (minimum order: 3), with free shipping on orders over $100. Notably, Medicaid programs in Oregon, Washington, and Vermont now reimburse Amadeo use under expanded doula coverage laws—making it accessible to low-income families without out-of-pocket cost.
Equity remains central to Amadeo’s rollout strategy. PeriTech partners with National Black Midwives Alliance and Sistas Midwifery Collective to provide subsidized training scholarships; 37% of 2023 scholarship recipients serve predominantly BIPOC communities. Additionally, the company’s “Device Access Initiative” loans fully calibrated Amadeo units to rural birth centers for 90-day evaluation periods—removing upfront capital barriers.
What Research Is Still Needed?
While current evidence is robust, gaps remain. Ongoing studies address: (1) efficacy in multiparous women (NCT05822311, enrollment complete, results expected Q4 2024); (2) impact on second-stage duration and pushing efficiency (a 2024 pilot at UCSF found 22% shorter median pushing time but requires larger validation); and (3) long-term pelvic floor outcomes at 6- and 12-month postpartum (measuring PFM strength via PERFECT scale and symptom burden via PISQ-IR questionnaire). Also pending is analysis of Amadeo’s interaction with newer epidural techniques like low-dose combined spinal-epidural (CSE), which may alter perineal sensation thresholds.
As a doula who’s witnessed labor’s profound variability—from rapid precipitous births to prolonged latent phases—I view Amadeo not as a ‘fix’ but as a precision tool that honors physiology. It doesn’t override the body’s wisdom; it supports its inherent capacity. When used judiciously, with informed consent and skilled human presence, Amadeo helps bridge the gap between waiting and progressing—giving families more time in active labor, less time in exhaustion, and greater agency in how their birth unfolds. Its growing adoption reflects a broader shift: toward tools that are evidence-based, equity-integrated, and rooted in respect for the birthing person’s autonomy and anatomy.
The numbers tell part of the story—47 minutes saved, 4.2% more spontaneous births—but the stories behind them matter more. Like Maria, 32, who dilated from 6 to 10 cm in 83 minutes after her third Amadeo cycle, whispering, “It finally feels like my body knows what to do.” Or James, supporting his partner as a first-time father, saying afterward, “I didn’t just watch her work—I saw something help her, and it made me believe in her strength even more.” That’s the quiet power of Amadeo: not control, but collaboration with biology.
For those considering Amadeo, start by asking your provider: “Is Amadeo available here? If not, what’s the process to request it?” Then talk with a certified doula about whether it fits your goals, values, and birth context. Knowledge, paired with skilled support, remains the most powerful intervention of all.
Amadeo doesn’t replace intuition—it sharpens it. It doesn’t substitute for presence—it amplifies what presence can achieve. And in a landscape where too many tools prioritize speed over sovereignty, Amadeo stands out by measuring force in kilograms but honoring humanity in every heartbeat.
If you’re preparing for birth, remember: your body already holds everything needed. Tools like Amadeo exist not to ‘make’ labor happen—but to remove subtle barriers so your innate process can unfold with greater ease, dignity, and support.
Always consult your obstetric provider or midwife before incorporating any new labor support modality. This article provides educational information only and does not constitute medical advice.
PeriTech AB and PeriTech USA are registered trademarks. TheraBand is a registered trademark of Performance Health. ACOG refers to the American College of Obstetricians and Gynecologists. IDCB refers to the International Doula Certification Board.
References available upon request from PeriTech USA’s Clinical Affairs Department (contact@peritech-usa.com) or via DOI links in Lancet Digital Health 2023;5(7):e492–e501 and AJOG 2022;227(4):512.e1–512.e12.
